Tempus AI (TEM) closed at $64.34 on Oct 19, 2026, down 0.6% on the day. The stock is down 17.3% over the past month, up 31.4% over three months, up 9.0% year to date and down 29.3% over the past year. It trades 33.2% below its 52-week high of $96.29 and 57.8% above its 52-week low of $40.77. The close sits below its 50-day moving average ($68.06) and above its 200-day moving average ($56.81).
NextPick tracks TEM in its AI Drug Discovery basket alongside ABCL, RXRX, SDGR, CERT and ABSI. As of Oct 19, 2026, the basket's money-flow score is -38 (outflow), and the basket is down 6.9% over five sessions. Over the past month TEM ranks 5th of 6 basket members by price change.
Form 4 filings over the last 90 days show no open-market purchases and 102 open-market sales by insiders.
Yes — the Oct 19, 2026 close of $64.34 is 13.3% above the 200-day average of $56.81.
TEM closed 33.2% below its 52-week high of $96.29.
NextPick groups TEM with ABCL, RXRX, SDGR, CERT and ABSI in its AI Drug Discovery basket.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
